4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company that designs and develops targeted gene therapies. The company leverages its proprietary Therapeutic Vector Evolution platform, which combines directed evolution with billions of synthetic adeno-associated virus (AAV) capsid sequences, to create customized delivery vehicles for genetic medicines. Its clinical pipeline is primarily focused on three therapeutic areas: ophthalmology, pulmonology, and cardiology. Key product candidates include 4D-150 for wet age-related macular degeneration and diabetic macular edema, as well as 4D-710 for cystic fibrosis lung disease. By engineering vectors that can efficiently penetrate target tissues while minimizing immune responses, 4D Molecular Therapeutics aims to provide durable, single-dose treatments for patients with high unmet medical needs.
